Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis

This publication has 40 references indexed in Scilit:

• Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment
  International Journal of Clinical Oncology, 2025
• Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta‐analysis of real‐world evidence
  Cancer, 2024
• Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study
  International Journal of Clinical Oncology, 2023
• Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
  Cancer Medicine, 2023
• Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas
  JAMA Oncology, 2022
• Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5‐fluorouracil and leucovorin
  Journal of Hepato-Biliary-Pancreatic Sciences, 2022
• Estimated Projection of US Cancer Incidence and Death to 2040
  JAMA Network Open, 2021
• Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience
  Medical Oncology, 2019
• Methods for including information from multi‐arm trials in pairwise meta‐analysis
  Research Synthesis Methods, 2017
• Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
  Drugs, 2017